With advancements in biomarkers and momentum in precision medicine, biomarker‐guided
trials such as basket trials and umbrella trials have been developed under the master …

Background Immune checkpoint inhibitors (ICI) either alone or in combination with
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …

Abstract Background The Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) checklist consists of 20 items to report for published tumor marker …

User-friendly and concise, the new edition of this popular reference is your# 1 guide for the
appropriate use of immunohistochemical stains. Dr. David J. Dabbs and leading experts in …

Recent advancements in breast cancer treatment have ushered in a new era of precision
medicine. Novel trials have led to the approval of a growing list of personalized therapies …

The body of literature on the correlations between molecular assessments and patient
outcomes after treatment with epidermal growth factor receptor (EGFR) inhibitors continues …

Purpose Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (HER2) with activity in HER2-amplified metastatic breast …

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …

It would be helpful to have factors that could identify patients who will, or will not, benefit from
treatment with specific therapies. Ideally, these should be molecular-based factors. When …

Purpose Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib
pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of …